Diuretic Selection and Dosing for Cardio-Renal Syndrome

Primary Loop Diuretic Selection

The American College of Cardiology recommends torsemide as the preferred loop diuretic in patients with cardio-renal syndrome, hypotension, and impaired renal function, due to its superior pharmacokinetics and consistent bioavailability 1, 2
Torsemide has a longer duration of action, allowing for once-daily dosing and reducing the risk of hypotensive episodes 1, 2, 3

The European Society of Cardiology suggests starting with torsemide 10-20 mg once daily, with potential escalation to 40-60 mg daily if congestion persists 1, 3
The American College of Cardiology recommends targeting a weight loss of 0.5-1.0 kg daily during active decongestion 1, 4
The guideline suggests increasing the torsemide dose by 20-40 mg increments every 3-5 days if inadequate response is observed 1, 4

The American College of Cardiology recommends adding metolazone 2.5 mg once daily to torsemide for diuretic resistance, with a maximum metolazone dose of 5-10 mg daily 5, 6
The combination of torsemide and metolazone increases natriuresis by blocking compensatory distal tubule sodium reabsorption 5, 6

The European Journal of Heart Failure suggests checking electrolytes and creatinine within 2-4 days after initiation and after each dose increase 7, 8
The American College of Cardiology recommends monitoring daily weights, jugular venous pressure, and orthostatic vital signs to balance decongestion against hypotension 4

The American College of Cardiology suggests avoiding furosemide in cardio-renal syndrome with hypotension due to its erratic absorption, shorter duration of action, and higher risk of ototoxicity 1, 3

The American College of Cardiology recommends ensuring patients are on an ACE inhibitor (or ARB if ACE-intolerant) and beta-blocker before aggressive diuretic escalation 1, 4
The guideline suggests that these agents prevent electrolyte depletion and provide mortality benefit that diuretics alone cannot achieve 1, 7

The American College of Cardiology recommends torsemide IV 20 mg bolus, then 5-20 mg/hour continuous infusion for hospitalized patients with severe congestion and inadequate oral response 5, 6
The guideline suggests that continuous infusion provides more sustained diuresis and avoids the hypotensive nadirs associated with intermittent boluses 5, 6

The European Heart Journal recommends that in patients with signs of hypoperfusion, diuretics should be avoided before adequate perfusion is attained, and once perfusion is restored, diuresis should continue until fluid retention is eliminated 9
The European Heart Journal suggests avoiding vasodilators, including high-dose levosimendan, when systolic blood pressure is <85-90 mmHg 9
The European Heart Journal advises eliminating factors blocking diuretic efficacy, including excessive dietary sodium intake, NSAIDs/COX-2 inhibitors, and ensuring patients are not volume depleted before initiating aggressive diuresis 9

The European Heart Journal recommends ensuring patients are on ACE inhibitor (or ARB if ACE-intolerant) and beta-blocker before aggressive diuretic escalation, as these agents prevent electrolyte depletion and provide mortality benefit that diuretics alone cannot achieve, but use beta-blockers cautiously in hypotensive patients 9